

SARS Epidemiology


The WHO SARS Team


30 May 2003 = day x+76

GLOBAL
HEALTH
SECURITY

WHO SARS Emergency Response

KS 23/3/3





Epidemiology → Today

- Epidemiological parameters
 - Risk groups, case-fatality ratio; age groups; incubation period
- Routes and patterns of transmission/infection
- Virus excretion (duration/amount/pattern)
- Asymptomatic, silent and chronic infection
- Discrepancies between clinical and laboratory findings
- Seasonal variability
- Animals as source of infection and/or reservoirs
- Origin and begin of outbreak
- Virus stability/tenacity in the environment
- Spectrum of illness
- Ab-kinetics; duration of immunity
- Superspreaders
- Co-infection, relapses
- Effectiveness of interventions

What will not be covered:


- Key developments in outbreak history and evolution
- Economical and health impact
- Emergence of SARS and Global Alert
- Travel recommendations
- Interventions and their effectiveness
- International collaboration and partners
- What we still need to know
- What we are learning
- Real and perceived risks
-
-

Outbreak began in 2002

- Serosurveys blood donors
 - Hong Kong
 - ~340 sera prior to SARS (blood donors) → all neg.
 - 200 sera (blood donors) during April 2003 → all neg
 - USA, CDC
 - 400 sera prior to SARS → all neg.
- Virus isolation/detection
 - Canada: 365 NPS from pre-SARS patients → all PCR neg.
- Epidemiology
 - No temporal/spatial clustering of 800 atypical pneumonia cases in Guangdong between 1999 and 2002




SARS Hong Kong: occupational risks: affected HCW




SARS Case-fatality rate: ~15%

- Age specific CFR China →
- CFR in individuals over 60
 - China: 72%
 - Canada: 83%
 - Hong Kong: >50%
- RF: age, male sex (HK), co-morbidity
- Influence of health care system unclear



SARS Incubation period



Reported at WHO SARS Epi Consultation 16 May 2003


GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

SARS incubation period

- Guangdong, 70 cases, single point-exposure



Reported at WHO SARS Epi Consultation 16 May 2003

GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

SARS Incubation period

- Detailed investigation of outliers is needed before public health policy is changed
 - Combination of 200 cases from 7 sites into international standardized dataset necessary to refining current IKP estimates
- Current data
 - 2-10 days; medium 5 days
 - Based on single point exposure cases or well-defined exposure interval from 7 sites
 - Do not allow to assess whether route of infection influences incubation period




GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

SARS virus excretion patterns

- Sequential sampling 20 patients with initial NPA RT-PCR + and sero-conversion




GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

SARS virus excretion patterns

- 392 NPA/TNS; 50 stool samples, HK SAR




GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

SARS virus excretion Amoy Garden

- RT-PCR (Artus), 34 stool samples; different patients




GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

Sequential quantitative RT-PCR levels NPA 14 SARS patients



From: Peris et.al. Lancet May 2003

GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

SARS Virus/RNA excretion

● Respiratory specimen

- Pasteur Inst Paris; one case: +32 days virus RNA detectable; Virus isolation failed

● Stool PCR pos

- Germany/Singapore: >42 days
- Hong Kong (Virus Unit): >49 days

● Conjunctiva

- Germany/Singapore: PCR pos day 1

● Virus isolation up to day 16



GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

SARS transmission pattern

- No evidence of transmission before onset of first symptoms
- A few cases thought to have transmitted in the early prodromal period (small # of source cases, Canada)
- Those who are very ill or experiencing rapid clinical deterioration, usually during second week of illness, are the most communicable
- No evidence of transmission 10 days post-fever resolution




GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

SARS Routes of transmission

- Primary mode
 - Direct mucous membrane contact with infectious respiratory droplets
- Events that promote aerosolisation of infectious ex/secretions/body fluids in hospitals or other settings, may amplify transmission
- Role of fecal-oral transmission remains unknown
- Contamination of materials and objects with ex/secretions and body fluids may play role in certain circumstances
 - Health care settings, closed environments
- No reports on food or water borne transmission



GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

SARS Routes of transmission

- Cases occurred primarily in those in close contact with very ill in health care settings and households
- Transmission to casual and social contacts has occasionally occurred
 - when there has been sustained, close contact with a case of SARS (in workplaces, airplanes or taxis) or in high-risk transmission settings, such as health care settings and households.
- No reports of transmission
 - to and between children
 - Vertical - blood



GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

SARS transmission on airplanes

- No documented airplane transmission after 23 March
- Facts
 - 41 flights with probable cases
 - 4 flights with total of 25 secondary cases
 - SQ25 New York–Frankfurt, 14 March 2003→ 3
 - CA112 Hong Kong–Beijing, 15 March 2003→18
 - TG614 Bangkok–Beijing, 23 March 2003→ 1
 - AF171 Hanoi– Bangkok– Paris, 22/23 March 2003→ 3



GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

Asymptomatic excretors

- Spectrum of disease still incompletely understood
- Hong Kong: Amoy garden during quarantine (HK Virus Unit)
 - One individual: seroconversion; virus isolation; PCR pos
 - 316 persons: 32 PCR pos in TNS (some positive up to 10 days)
 - Serolog data pending, Sampling time unknown; mild disease? (ILI; diarrhea)
 - 162 sera (2 April)
 - 1 Ab positive (IFA)→ also positive by PCR in throat swab
- Canada
 - Two individuals without any links to SARS patients or history of disease: virus isolation from stool
- No reports on transmission from asymptomatic individuals

GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

Sero-conversion without disease

- Healthy HCW seroconverted
 - Hong Kong: 3 out of 500 HCW (Prince Wales H) pos by IFA
 - Two with fever episode
 - China: some ...
- Guandong: 5 out of 10 wild animal traders from one live animal marked seroconverted (IFA)

GLOBAL
HEALTH
SECURITY

WHO SARS Coordination and Response

KS 27/05/03

Virus/RNA excretion without seroconversion

- Hong Kong Virus Unit
 - Several (3-4) individuals PCR pos without seroconversion (day 32)

Virus stability

- Virus survives
 - stool and urine for at least 2 days
 - diarrhoeal stool up to 4 days
 - dried at room temperature at least 2 days
 - Acetone fixed slides
 - At -4 °C and -80 °C at least 21 days with minimal reduction
- Does Not survive
 - Usually used disinfectant
 - Temp 56 °C for 30 min in blood serum
 - fixed In infected cells after -20 °C Acetone fixation

SARS Animal testing Summary

● Trials

- Pigs and turkey: challenge (Canada)
- Rabbits, guinea pigs, mice: serum prod (Canada)
- Japanese quail, chicken, ducks (ongoing) (Georgia, USA)
- Non-human primates (Rotterdam; USAMRID; China) → only animal models
- Rodents (mice; rats): France; China



● Environment

- Amoy garden
 - Cats: 2 of 4 seroconverted; one PCR throat pos
 - Dog: PCR-pos in feces (quantity unknown)
 - Cockroaches: droppings and intestinal content pos; no isolation from tissue
 - Rat: droppings pos PCR

SARS Animal reservoir?

- Shenzhen live animal market; 3 samplings; 8 species; 25 animals
- Masked Palm Civets
 - 6/6 virus isolation or PCR pos (nasal/fecal)
 - 3/4 neutralizing Ab titre
- Raccoon dog
 - Virus isolation
- Chinese ferret badger
 - Neutralizing Ab titre
- 4 isolates sequenced; cross-neutralization tests



Research

- Infectious period; excretion patterns
 - Infection control; diagnostic test development
- Routes of transmission; exposure dose
- Measures on preventing transmission
- Vertical transmission; children
- Sub-clinical infection
- Animal and environmental reservoirs

